Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT (2016 - 2025)

Historic EBT for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.9 million.

  • Enanta Pharmaceuticals' EBT rose 4752.93% to -$11.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$72.8 million, marking a year-over-year increase of 3166.11%. This contributed to the annual value of -$83.5 million for FY2025, which is 2906.83% up from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported EBT of -$11.9 million as of Q4 2025, which was up 4752.93% from -$18.7 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' EBT's 5-year high stood at -$11.9 million during Q4 2025, with a 5-year trough of -$37.6 million in Q1 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median EBT value was -$29.4 million (recorded in 2023), while the average stood at -$28.1 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' EBT tumbled by 19375.31% in 2021 and then skyrocketed by 4752.93% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBT (Quarter) stood at -$30.2 million in 2021, then grew by 3.75% to -$29.0 million in 2022, then decreased by 17.26% to -$34.0 million in 2023, then surged by 33.27% to -$22.7 million in 2024, then soared by 47.53% to -$11.9 million in 2025.
  • Its last three reported values are -$11.9 million in Q4 2025, -$18.7 million for Q3 2025, and -$18.2 million during Q2 2025.